|
|
 |
|
DVAX: Dynavax Technologies Cp - Stock News |
Enter Ticker:
|
|
| Nov 20, 2009 |
DVAX Completes Hep-B Enrollment |
| Nov 19, 2009 |
Dynavax Completes Enrollment of First Cohort of Patients in Phase 1bClinical Trial for Hepatitis B Therapy |
| Nov 19, 2009 |
Dynavax Technologies Down 31.1% Since SmarTrend's Sell Recommendation |
| Nov 11, 2009 |
Dynavax Technologies Down 28% Since SmarTrend's Sell Recommendation |
| Nov 10, 2009 |
PreMarketData.com: PreMarketData.com Early Session Standouts For Tuesday Include PCLN, XNOM, DVAX |
| Nov 10, 2009 |
Dynavax Technologies Buys Symphony Dynamo (DVAX) |
| Nov 10, 2009 |
Dynavax to Acquire Symphony Dynamo, Including $20 Mln in Unrestricted Cash, Hepatitis and Cancer Therapy Programs |
| Nov 10, 2009 |
Dynavax to Acquire Symphony Dynamo, Inc., Including $20 Million inUnrestricted Cash |
| Nov 05, 2009 |
Dynavax Appoints Francis R. Cano, Ph.D. to Board of Directors |
| Nov 02, 2009 |
Dynavax Technologies Down 37.3% Since SmarTrend's Sell Recommendation |
| Oct 30, 2009 |
United States : Dynavax Technologies announces first clinical data for HEPLISAV investigational hepatitis B vaccine |
| Oct 30, 2009 |
BiomedReports: News and FDA Updates for Human Genome Sciences (Nasdaq:HGSI), ImmunoGen (Nasdaq:IMGN), Dynavax (Nasdaq:DVAX) |
| Oct 29, 2009 |
Dynavax's HEPLISAV Shows Increased Protection Rate for Chronic Kidney Disease Patients |
| Oct 28, 2009 |
Dynavax Releases 3Q and 9 Months 2009 Financial Results |
| Oct 27, 2009 |
Dynavax Technologies Down 34.2% Since SmarTrend's Sell Recommendation |
| |
| ZACKS COMMENTARY FOR DVAX |
|
|
|
Sponsored Links 
0.02